Zacks Research Lifts Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research increased their Q4 2027 EPS estimates for Globus Medical in a report issued on Thursday, August 27th. Zacks Research analyst Team now expects that the medical device company will post earnings of $1.37 per share for the quarter, up from their prior estimate of $1.22. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.99 per share. Zacks Research also issued estimates for Globus Medical’s FY2028 earnings at $5.88 EPS.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company cut their price objective on Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Truist Financial decreased their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Royal Bank Of Canada dropped their price target on Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. BMO Capital Markets initiated coverage on shares of Globus Medical in a report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price target on the stock. Finally, UBS Group started coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and an average price target of $101.77.

Globus Medical Price Performance

GMED opened at $81.44 on Monday. The business has a 50 day simple moving average of $81.18 and a two-hundred day simple moving average of $84.54. The firm has a market capitalization of $10.93 billion, a price-to-earnings ratio of 20.83, a PEG ratio of 1.34 and a beta of 0.95. Globus Medical has a one year low of $54.15 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.10 by $0.24. The firm had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

Insider Buying and Selling

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The SEC filing for this sale provides additional information. 18.38% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Globus Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC grew its position in shares of Globus Medical by 2.3% in the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock worth $570,000 after buying an additional 151 shares during the period. SBI Securities Co. Ltd. boosted its stake in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares in the last quarter. Parallel Advisors LLC grew its holdings in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of Globus Medical by 1.6% during the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after purchasing an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.